<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00063934</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02885</org_study_id>
    <secondary_id>NCI-2012-02885</secondary_id>
    <secondary_id>6023</secondary_id>
    <secondary_id>DM02-700</secondary_id>
    <secondary_id>6023</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>N01CM17003</secondary_id>
    <nct_id>NCT00063934</nct_id>
  </id_info>
  <brief_title>Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer</brief_title>
  <official_title>A Phase 1/2 Study of Bcl-2 Antisense Oligonucleotide G3139 in Combination With Doxorubicin and Docetaxel in Metastatic and Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I/II trial is studying the side effects and best dose of oblimersen when given
      together with doxorubicin and docetaxel and to see how well they work in treating women with
      metastatic or locally advanced breast cancer. Drugs used in chemotherapy, such as doxorubicin
      and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing
      or die. Oblimersen may increase the effectiveness of doxorubicin and docetaxel by making the
      tumor cells more sensitive to the drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the pharmacokinetics of G3139, doxorubicin and docetaxel in breast cancer
      patients receiving G3139/AT therapy. (Phase I) II. To determine the safety of bcl-2 antisense
      oligonucleotide G3139 (GenasenseTM) together with docetaxel plus doxorubicin (AT) in patients
      with metastatic and locally advanced breast cancer (LABC). (Phase I) III. To determine the
      therapeutic efficacy of neoadjuvant G3139 in combination with AT chemotherapy in patients
      with LABC. (Phase II) IV. To further evaluate the safety of bcl-2 antisense oligonucleotide
      G3139 (GenasenseTM) together with docetaxel plus doxorubicin (AT) in patients with locally
      advanced breast cancer (LABC). (Phase II)

      SECONDARY OBJECTIVES:

      I. To determine the clinical and imaging response to neoadjuvant G3139/AT in the breast and
      the axillary lymph nodes. (Phase II) II. To determine the disease-free survival of breast
      cancer patients treated with neoadjuvant G3139/AT. (Phase II) III. To further define the
      pharmacokinetics of G3139/AT. (Phase II) IV. To evaluate the role of Bcl-2 expression as a
      predictor of response to neoadjuvant G3139/AT therapy. (Phase II) V. To obtain serial breast
      cancer samples from patients treated with G3139. (Phase II)

      OUTLINE: This is an open-label, dose-escalation study of oblimersen.

      PHASE I (COMPLETED AS OF 8/16/04): Patients receive oblimersen IV continuously on days 1-6
      interrupted only to administer doxorubicin IV over 15 minutes and docetaxel IV over 60
      minutes on day 6. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 7-13
      or pegfilgrastim SC on day 7. Treatment repeats every 21 days for up to 6 courses in the
      absence of disease progression or unacceptable toxicity.

      Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2
      of 6 patients experience dose-limiting toxicity.

      PHASE II: Patients receive doxorubicin, docetaxel, G-CSF or pegfilgrastim, and oblimersen at
      the MTD as in phase I.

      Patients with resectable tumors after 6 courses undergo surgical resection.

      Patients are followed every 3-6 months for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant Toxicity</measure>
    <time_frame>From baseline to study completion, every 3 weeks</time_frame>
    <description>Incidence of toxicity summarized using NCI Common Toxicity Criteria, version 3.0 every 3 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Pathologic Complete Response (pCR)</measure>
    <time_frame>At time of definitive surgery (after 6 courses of neoadjuvant therapy in 3 week cycles), approximately 18 weeks</time_frame>
    <description>Pathologic complete responses (pCR), defined as no evidence of residual invasive tumor, including no residual tumor in the axillary lymph nodes, measured by microscopic evaluation of tissue specimen at time of definitive surgery (after 6 courses of neoadjuvant therapy). Neoadjuvant (preoperative) therapy administered on the first five days of every 3-week cycle. Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Imaging Responses</measure>
    <time_frame>After 3 and 6 courses of 21 day treatments (up to 18 weeks)</time_frame>
    <description>Evaluation target lesions (clinical response) by physical exam/ultrasound measurements of primary tumor and axillary lymph nodes after 3-6 courses: Complete Response: Disappearance of all target lesions; Partial Response: &gt;30% decrease in sum longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease: &gt;20% increase in sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of 1&gt;new lesions; Stable Disease: Neither sufficient shrinkage for PR nor increase for PD, reference smallest sum LD since treatment started.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bcl-2 Expression in Breast Cancer Tissue</measure>
    <time_frame>before treatment and at 3-5 days after oblimersen treatment</time_frame>
    <description>Number of participant with Bcl-2 Expression in breast cancer tissue by protein and mRNA expression before treatment and at 3-5 days after oblimersen treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Male Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (oblimersen, doxorubicin, docetaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHASE I (COMPLETED AS OF 8/16/04): Patients receive oblimersen IV continuously on days 1-6 interrupted only to administer doxorubicin IV over 15 minutes and docetaxel IV over 60 minutes on day 6. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 7-13 or pegfilgrastim SC on day 7. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
PHASE II: Patients receive doxorubicin, docetaxel, G-CSF or pegfilgrastim, and oblimersen at the MTD as in phase I.
Patients with resectable tumors after 6 courses undergo surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>oblimersen sodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (oblimersen, doxorubicin, docetaxel)</arm_group_label>
    <other_name>augmerosen</other_name>
    <other_name>G3139</other_name>
    <other_name>G3139 bcl-2 antisense oligodeoxynucleotide</other_name>
    <other_name>Genasense</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (oblimersen, doxorubicin, docetaxel)</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (oblimersen, doxorubicin, docetaxel)</arm_group_label>
    <other_name>RP 56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>TXT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (oblimersen, doxorubicin, docetaxel)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (oblimersen, doxorubicin, docetaxel)</arm_group_label>
    <other_name>Filgrastim SD-01</other_name>
    <other_name>GCSF-SD01</other_name>
    <other_name>Neulasta</other_name>
    <other_name>SD-01 sustained duration G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo surgical resection</description>
    <arm_group_label>Treatment (oblimersen, doxorubicin, docetaxel)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Treatment (oblimersen, doxorubicin, docetaxel)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Treatment (oblimersen, doxorubicin, docetaxel)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PHASE I: Patients must have histologically or cytologically confirmed breast cancer

          -  PHASE I: To be eligible for the phase I component of this study, patients must have
             stage IIIB, IIIC or IV breast cancer; these include patients with T4, any N, M0; any
             T, N3, M0; any T, any N, M1

          -  PHASE I: Measurable disease is not required for patients participating in the phase I
             component

          -  PHASE I: Prior G3139, taxane or anthracycline therapy is not allowed

          -  PHASE I: Patients may have received up to 3 prior chemotherapy regimens for breast
             cancer (excluding anthracyclines and taxanes), either as adjuvant/neoadjuvant therapy
             or for metastatic disease

          -  PHASE I: Life expectancy of greater than 6 months

          -  PHASE I: ECOG performance status =&lt; 2 (Karnofsky &gt;= 60%)

          -  PHASE I: Leukocytes &gt;= 3,000/L

          -  PHASE I: Absolute neutrophil count &gt;= 1,500/L

          -  PHASE I: Platelets &gt;= 100,000/L

          -  PHASE I: Total bilirubin =&lt; 1.5 mg/dl

          -  PHASE I: ALT(SGPT) =&lt; 2.5 X upper limit of normal

          -  PHASE I: Creatinine =&lt; 2.0 mg/dl

          -  PHASE I: Normal cardiac function (LVEF &gt;= 45%) as documented by MUGA scan and/or
             echocardiogram

          -  PHASE I: The effects of G3139 on the developing human fetus at the recommended
             therapeutic dose are unknown; for this reason and because anthracycline and taxanes
             used in this trial are known to be teratogenic, women of child-bearing potential and
             men must agree to use adequate contraception (hormonal or barrier method of birth
             control; abstinence) prior to study entry and for the duration of study participation;
             should a woman become pregnant or suspect she is pregnant while participating in this
             study, she should inform her treating physician immediately

          -  PHASE I: Ability to understand and the willingness to sign a written informed consent
             document

          -  PHASE II: Patients must have histologically or cytologically confirmed breast cancer

          -  PHASE II: Patients must have stage IIIA, IIIB, or IIIC breast cancer; these include
             patients with T4, any N, M0; any T, N2-3, M0; T3, N1, M0; patients with ipsilateral
             supraclavicular lymph node metastases (IIIC) are eligible; patients with evidence of
             distant metastases (stage IV) are not eligible

          -  PHASE II: Measurable disease is required; disease will be measured prior to initiation
             of G3139/doxorubicin/docetaxel therapy by physical exam, mammography and ultrasound of
             the affected areas; pathologic response will be measured at the time of definitive
             surgery

          -  PHASE II: Prior G3139 therapy is not allowed

          -  PHASE II: Prior chemotherapy, hormone therapy, definitive surgery, or radiation
             therapy for breast cancer are not allowed

          -  PHASE II: Life expectancy of greater than 6 months

          -  PHASE II: ECOG performance status =&lt; 2 (Karnofsky &gt;= 60%)

          -  PHASE II: Leukocytes &gt;= 3,000/L

          -  PHASE II: Absolute neutrophil count &gt;= 1,500/L

          -  PHASE II: Platelets &gt;= 100,000/L

          -  PHASE II: Total bilirubin =&lt; 1.5 mg/dl

          -  PHASE II: ALT(SGPT) =&lt; 2.5 X upper limit of normal

          -  PHASE II: Creatinine =&lt; 2.0 mg/dl

          -  PHASE II: Normal cardiac function (LVEF &gt;= 45%) as documented by MUGA scan and/or
             echocardiogram

          -  PHASE II: The effects of G3139 on the developing human fetus at the recommended
             therapeutic dose are unknown; for this reason and because anthracycline and taxanes
             used in this trial are known to be teratogenic, women of child-bearing potential and
             men must agree to use adequate contraception (hormonal or barrier method of birth
             control; abstinence) prior to study entry and for the duration of study participation;
             should a woman become pregnant or suspect she is pregnant while participating in this
             study, she should inform her treating physician immediately

          -  PHASE II: Ability to understand and the willingness to sign a written informed consent
             document

        Exclusion Criteria:

          -  PHASE I: Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks
             for nitrosoureas or mitomycin C) prior to entering the phase I study or those who have
             not recovered from adverse events due to agents administered more than 4 weeks earlier

          -  PHASE I: Patients may not be receiving any other investigational agents

          -  PHASE I: Patients with known brain metastases should be excluded from this clinical
             trial because of their poor prognosis and because they often develop progressive
             neurologic dysfunction that would confound the evaluation of neurologic and other
             adverse events

          -  PHASE I: Leptomeningeal disease

          -  PHASE I: Symptomatic lymphangitic pulmonary metastases

          -  PHASE I: History of allergic reactions attributed to compounds of similar chemical or
             biologic composition to G3139 or other agents used in the study; patients are excluded
             if known hypersensitivity to drugs formulated in polysorbate 80 (Tween 80)

          -  PHASE I: Uncontrolled intercurrent illness including, but not limited to, ongoing or
             active infection, symptomatic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements

          -  PHASE I: Patients with neuropathy grade 2 or higher

          -  PHASE I: Pregnant women are excluded from this study because G3139 is an
             oligonucleotide agent with the potential for teratogenic or abortifacient effects;
             because there is an unknown but potential risk for adverse events in nursing infants
             secondary to treatment of the mother with G3139, breastfeeding should be discontinued
             if the mother is treated with G3139; these potential risks may also apply to other
             agents used in this study, such as doxorubicin and docetaxel

          -  PHASE II: Patients may not be receiving any other investigational agents

          -  PHASE II: History of allergic reactions attributed to compounds of similar chemical or
             biologic composition to G3139 or other agents used in the study; patients are excluded
             if known hypersensitivity to drugs formulated in polysorbate 80 (Tween 80)

          -  PHASE II: Uncontrolled intercurrent illness including, but not limited to, ongoing or
             active infection, symptomatic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements

          -  PHASE II: Patients with neuropathy grade 2 or higher

          -  PHASE II: Pregnant women are excluded from this study because G3139 is an
             oligonucleotide agent with the potential for teratogenic or abortifacient effects;
             because there is an unknown but potential risk for adverse events in nursing infants
             secondary to treatment of the mother with G3139, breastfeeding should be discontinued
             if the mother is treated with G3139; these potential risks may also apply to other
             agents used in this study, such as doxorubicin and docetaxel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Esteva</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <results_first_submitted>July 10, 2012</results_first_submitted>
  <results_first_submitted_qc>July 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2012</results_first_posted>
  <last_update_submitted>May 6, 2014</last_update_submitted>
  <last_update_submitted_qc>May 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Oblimersen</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: May 16, 2003 to August 25, 2005; All recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 31 participants enrolled, one participant was ineligible for treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oblimersen Plus Doxorubicin + Docetaxel</title>
          <description>Intravenous Oblimersen 7 mg/kg/day, both Doxorubicin 50 mg/m^2 and Docetaxel 75 mg/m^2 infused on Day 6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oblimersen Plus Doxorubicin + Docetaxel</title>
          <description>Intravenous Oblimersen 7 mg/kg/day, both Doxorubicin 50 mg/m^2 and Docetaxel 75 mg/m^2 infused on Day 6</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="24" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participant Toxicity</title>
        <description>Incidence of toxicity summarized using NCI Common Toxicity Criteria, version 3.0 every 3 weeks.</description>
        <time_frame>From baseline to study completion, every 3 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pathologic Complete Response (pCR)</title>
        <description>Pathologic complete responses (pCR), defined as no evidence of residual invasive tumor, including no residual tumor in the axillary lymph nodes, measured by microscopic evaluation of tissue specimen at time of definitive surgery (after 6 courses of neoadjuvant therapy). Neoadjuvant (preoperative) therapy administered on the first five days of every 3-week cycle. Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]</description>
        <time_frame>At time of definitive surgery (after 6 courses of neoadjuvant therapy in 3 week cycles), approximately 18 weeks</time_frame>
        <population>Intention to treat eligible participants per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Oblimersen Plus Doxorubicin + Docetaxel</title>
            <description>Intravenous Oblimersen 7 mg/kg/day, both Doxorubicin 50 mg/m^2 and Docetaxel 75 mg/m^2 infused on Day 6</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pathologic Complete Response (pCR)</title>
          <description>Pathologic complete responses (pCR), defined as no evidence of residual invasive tumor, including no residual tumor in the axillary lymph nodes, measured by microscopic evaluation of tissue specimen at time of definitive surgery (after 6 courses of neoadjuvant therapy). Neoadjuvant (preoperative) therapy administered on the first five days of every 3-week cycle. Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]</description>
          <population>Intention to treat eligible participants per protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Imaging Responses</title>
        <description>Evaluation target lesions (clinical response) by physical exam/ultrasound measurements of primary tumor and axillary lymph nodes after 3-6 courses: Complete Response: Disappearance of all target lesions; Partial Response: &gt;30% decrease in sum longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease: &gt;20% increase in sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of 1&gt;new lesions; Stable Disease: Neither sufficient shrinkage for PR nor increase for PD, reference smallest sum LD since treatment started.</description>
        <time_frame>After 3 and 6 courses of 21 day treatments (up to 18 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oblimersen Plus Doxorubicin + Docetaxel</title>
            <description>Intravenous Oblimersen 7 mg/kg/day, both Doxorubicin 50 mg/m^2 and Docetaxel 75 mg/m^2 infused on Day 6</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Imaging Responses</title>
          <description>Evaluation target lesions (clinical response) by physical exam/ultrasound measurements of primary tumor and axillary lymph nodes after 3-6 courses: Complete Response: Disappearance of all target lesions; Partial Response: &gt;30% decrease in sum longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease: &gt;20% increase in sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of 1&gt;new lesions; Stable Disease: Neither sufficient shrinkage for PR nor increase for PD, reference smallest sum LD since treatment started.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bcl-2 Expression in Breast Cancer Tissue</title>
        <description>Number of participant with Bcl-2 Expression in breast cancer tissue by protein and mRNA expression before treatment and at 3-5 days after oblimersen treatment.</description>
        <time_frame>before treatment and at 3-5 days after oblimersen treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oblimersen Plus Doxorubicin + Docetaxel</title>
            <description>Intravenous Oblimersen 7 mg/kg/day, both Doxorubicin 50 mg/m^2 and Docetaxel 75 mg/m^2 infused on Day 6</description>
          </group>
        </group_list>
        <measure>
          <title>Bcl-2 Expression in Breast Cancer Tissue</title>
          <description>Number of participant with Bcl-2 Expression in breast cancer tissue by protein and mRNA expression before treatment and at 3-5 days after oblimersen treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years and 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oblimersen Plus Doxorubicin + Docetaxel</title>
          <description>Intravenous Oblimersen 7 mg/kg/day, both Doxorubicin 50 mg/m^2 and Docetaxel 75 mg/m^2 infused on Day 6</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, non-neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Infection or fever with Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Vision (other)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Heartburn/Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drug fever</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory Neuropathy</sub_title>
                <description>Neurolgy</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis/Itching</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Francisco Esteva, MD, PHD / Professor</name_or_title>
      <organization>UTMDACC</organization>
      <phone>713-792-2817</phone>
      <email>nsyates@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

